Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Takes Hint From Regulators In Pulling Zactima Applications

This article was originally published in The Pink Sheet Daily

Executive Summary

An updated analysis showing no overall survival advantage for vandetanib, plus feedback from both FDA and EMEA that progression-free survival was not enough, caused AstraZeneca to withdraw the filings.
Advertisement

Related Content

Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs
Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs
FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients
FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
Toxicity Of AstraZeneca's Vandetanib Expected Focus For FDA Advisory Committee
Advisory Panel To Consider Vandetanib's New Life In Niche Thyroid Cancer
FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee
ASCO IN BRIEF
ASCO IN BRIEF

Topics

Advertisement
UsernamePublicRestriction

Register

PS068667

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel